---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-342669"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2026-08-10T21:14:42+00:00"
generated_at: "2026-08-10T21:16:12.558612+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Erasca appoints Charles Fuchs as President, R&D; adopts 2026 inducement plan

## Summary
- Charles S. Fuchs, M.D., M.P.H., appointed President, R&D effective Aug 10, 2026.
- Prior roles: CMO at Tubulis (acquired by Gilead), SVP Global Head Oncology at Genentech/Roche, Yale Cancer Center director.
- Compensation: $570k base, 45% target bonus, stock options for 1.3M shares vesting over 4 years.
- Inducement Plan adopted, reserving 6.2M shares for equity awards without stockholder approval.
- Options: 1,278,520 under new Inducement Plan, remainder under 2021 Incentive Plan; exercise price at close on grant date.

## SEC filing metadata
- accession: 0001193125-26-342669
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2026-08-10T21:14:42+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000119312526342669/0001193125-26-342669-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000119312526342669/eras-20260810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-342669
- JSON: https://secwatch.observer/filing/0001193125-26-342669.json
- Plain text: https://secwatch.observer/filing/0001193125-26-342669.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.